Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Patrizia Vici, Laura Pizzuti, Clara Natoli, Luca Moscetti, Lucia Mentuccia, Angela Vaccaro, Domenico Sergi, Luigi Di Lauro, Patrizia Trenta, Patrizia Seminara, Daniele Santini, Laura Iezzi, Nicola Tinari, Ilaria Bertolini, Valentina Sini, Marcella Mottolese, Diana Giannarelli, Francesco Giotta, Marcello Maugeri-Saccà, Maddalena BarbaPaolo Marchetti, Andrea Michelotti, Isabella Sperduti, Teresa Gamucci

Research output: Contribution to journalArticlepeer-review

Abstract

Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted in selected patient populations, we performed a retrospective analysis of HER2-positive early breast cancer patients treated in the “pre-trastuzumab” and “trastuzumab” eras, with the aim to determine patients' outcomes in real-world practice. 925 consecutive HER2-positive breast cancer patients treated with adjuvant chemotherapy in ten Italian oncologic centers were identified. Patients who had received adjuvant chemotherapy alone (cohort A, 352 patients), and patients who had received adjuvant chemotherapy followed or combined with trastuzumab (cohort B, 573 patients) were analyzed. Relapse rate at 3 years, relapse-free survival, and overall survival were significantly more unfavorable in the cohort A than in the cohort B (p 

Original languageEnglish
Pages (from-to)599-607
Number of pages9
JournalBreast Cancer Research and Treatment
Volume147
Issue number3
DOIs
Publication statusPublished - Sep 24 2014

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • HER2-positive
  • Trastuzumab
  • Triple positive tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study'. Together they form a unique fingerprint.

Cite this